Protesting FDA misinformation

This week, APC took a firm stand against government misinformation by sending a strongly worded letter to the FDA challenging its recent statement on compounded GLP-1 medications.

The FDA’s claims — based on unverified FAERS data — misrepresent the safety of compounded therapies and unfairly alarm the public. Even more troubling, the agency has not applied the same scrutiny to FDA-approved GLP-1 drugs, despite exponentially more adverse event reports associated with them.

As compounders, we know our work — providing customized therapies for patients who need them — is essential. But when misinformation — whether from media, special interests, or even from regulators like FDA — threatens patient access and trust, we must push back. Silence is not an option. That’s why we’ve shared our letter with the news media as well.

APC will continue to defend the integrity of pharmacy compounding, ensuring regulators, lawmakers, and the public have the facts. We urge our members to stay engaged and ready to advocate. Let’s stand together to protect the future of compounding.